Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Premiums	$ 352,229	$ 308,810	$ 290,827
Investment and other income	3,920	5,202	4,089
Total revenues	447,567	400,278	371,622
Operating costs:
Medical costs	313,995	264,185	241,894
Operating costs	59,592	53,013	54,628
Cost of products sold	50,655	46,694	38,770
Depreciation and amortization	4,361	4,099	3,972
Total operating costs	428,603	367,991	339,264
Earnings from operations	18,964	32,287	32,358
Interest expense	(4,002)	(3,906)	(3,246)
Loss on sale of subsidiary and subsidiaries held for sale	(265)	(8,310)	0
Total income before income taxes	14,697	20,071	29,112
Provision for income taxes	(1,890)	(4,829)	(5,968)
Net earnings	12,807	15,242	23,144
Earnings attributable to noncontrolling interests	(751)	(837)	(763)
Net earnings attributable to UnitedHealth Group common shareholders	$ 12,056	$ 14,405	$ 22,381
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic	$ 13.28	$ 15.64	$ 24.12
Diluted	$ 13.23	$ 15.51	$ 23.86
Basic weighted-average number of common shares outstanding	908	921	928
Dilutive effect of common share equivalents	3	8	10
Diluted weighted-average number of common shares outstanding	911	929	938
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	12	6	6
Products
Revenues:
Revenue from Products and Services	$ 53,380	$ 50,226	$ 42,583
Services
Revenues:
Revenue from Products and Services	$ 38,038	$ 36,040	$ 34,123

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Operating activities
Net earnings	$ 12,807	$ 15,242	$ 23,144
Noncash items:
Depreciation and amortization	4,361	4,099	3,972
Deferred income taxes	(1,752)	(296)	(245)
Share-based compensation	971	1,018	1,059
Loss on sale of subsidiary and subsidiaries held for sale	265	8,310	0
Net gains on dispositions and other strategic transactions	(910)	(3,333)	(489)
Other, net	1,673	(28)	(16)
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable	(764)	(1,437)	(3,114)
Other assets	(4,606)	(4,140)	(2,444)
Medical costs payable	5,824	2,503	3,482
Accounts payable and other liabilities	1,665	2,463	3,516
Unearned revenues	163	(197)	203
Cash flows from operating activities	19,697	24,204	29,068
Investing activities
Purchases of investments	(17,373)	(27,308)	(18,314)
Sales of investments	9,288	18,514	7,307
Maturities of investments	8,446	9,319	9,230
Cash paid for acquisitions and other transactions, net of cash assumed	(4,509)	(13,408)	(10,136)
Purchases of property, equipment and capitalized software	(3,622)	(3,499)	(3,386)
Loans to care providers - cyberattack	0	(9,033)	0
Repayments of care provider loans - cyberattack	1,680	4,514	0
Cash received from dispositions, net	561	2,041	685
Originations and purchases of loans	(4,795)	(2,477)	(1,664)
Repayments and maturities of loans	1,980	908	613
Other, net	(341)	(98)	91
Cash flows used for investing activities	(8,685)	(20,527)	(15,574)
Financing activities
Common share repurchases	(5,545)	(9,000)	(8,000)
Cash dividends paid	(7,916)	(7,533)	(6,761)
Proceeds from common stock issuances	827	1,846	1,353
Repayments of long-term debt	(3,050)	(3,000)	(2,125)
Proceeds from (repayments of) short-term borrowings, net	807	(151)	11
Proceeds from issuance of long-term debt	2,969	17,811	6,394
Customer funds administered	366	(1,560)	(521)
Purchases of redeemable noncontrolling interests	(165)	(280)	(730)
Other, net	63	(1,645)	(1,150)
Cash flows used for financing activities	(11,644)	(3,512)	(11,529)
Effect of exchange rate changes on cash and cash equivalents	40	(61)	97
(Decrease) increase in cash and cash equivalents, including cash within businesses held for sale	(592)	104	2,062
Less: net increase in cash within businesses held for sale	(355)	(219)	0
Net (decrease) increase in cash and cash equivalents	(947)	(115)	2,062
Cash and cash equivalents, beginning of period	25,312	25,427	23,365
Cash and cash equivalents, end of period	24,365	25,312	25,427
Supplemental cash flow disclosures
Cash paid for interest	4,030	3,594	3,035
Cash paid for income taxes	$ 3,714	$ 4,620	$ 6,078

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 24,365	$ 25,312
Short-term investments	3,756	3,801
Accounts receivable, net of allowances of $1,208 and $985	23,018	22,365
Other current receivables, net of allowances of $3,763 and $2,864	29,697	26,089
Prepaid expenses and other current assets	9,746	8,212
Total current assets	90,582	85,779
Long-term investments	54,251	52,354
Property, equipment and capitalized software, net of accumulated depreciation and amortization of $7,546 and $6,971	10,762	10,553
Goodwill	110,499	106,734
Other intangible assets, net of accumulated amortization of $7,472 and $8,350	20,474	23,268
Other assets	23,013	19,590
Total assets	309,581	298,278
Current liabilities:
Medical costs payable	39,337	34,224
Accounts payable and accrued liabilities	38,032	34,337
Short-term borrowings and current maturities of long-term debt	6,069	4,545
Unearned revenues	3,413	3,317
Other current liabilities	28,046	27,346
Total current liabilities	114,897	103,769
Long-term debt, less current maturities	72,320	72,359
Deferred income taxes	2,421	3,620
Other liabilities	18,245	15,939
Total liabilities	207,883	195,687
Commitments and contingencies (Note 12)
Redeemable noncontrolling interests	1,608	4,323
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 906 and 915 issued and outstanding	9	9
Additional paid-in capital	559	0
Retained earnings	95,603	96,036
Accumulated other comprehensive loss	(2,061)	(3,387)
Nonredeemable noncontrolling interests	5,980	5,610
Total equity	100,090	98,268
Total liabilities and shareholders’ equity	$ 309,581	$ 298,278